Mol. Cells 2017; 40(6): 418~425  https://doi.org/10.14348/molcells.2017.0051
IP-10 Expression in Patients with Chronic HBV Infection and Its Ability to Predict the Decrease in HBsAg Levels after Treatment with Entecavir
Kai Zhao1,4, Tao Yang2,4, Mimi Sun3, Wei Zhang3, Yong An3, Gang Chen3, Lei Jin2, Qinghua Shang3,*, and
Wengang Song1,*
1Institute of Immunology, Taishan Medical University, Tai’an 271000, China, 2Research Centre for Biological Therapy, Institute of
Translational Hepatology, Beijing 302 Hospital, Beijing 100039, China, 3Department of Liver Disease, the 88th Hospital of PLA,
Tai’an 271000, China, 4These authors contributed equally to this work.
*Correspondence: shangqh@163.com (QHS); s.com@163.com (WGS)
Received March 23, 2017; Revised May 6, 2017; Accepted May 11, 2017.; Published online June 14, 2017.
© Korean Society for Molecular and Cellular Biology. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit (http://creativecommons.org/licenses/by-nc-sa/3.0/).
ABSTRACT
Interferon-γ-inducible protein 10 (IP-10), also known as chemokine C-X-C motif ligand (CXCL) 10, is closely associated with antiviral immunity and the progression of chronic hepatitis B (CHB). However, the value of baseline serological and histological IP-10 expression levels in predicting the efficacy of the antiviral response to nucleoside/nucleotide analogues (NAs) is still unknown. In our research, intrahepatic and peripheral IP-10 expression levels were systemically examined before and after treatment with entecavir (ETV). Baseline serological and histological IP-10 expression levels were significantly increased in patients with CHB, particularly in patients with higher degrees of liver inflammation and liver fibrosis. Moreover, higher baseline intrahepatic IP-10 levels indicated better prognoses in patients with CHB after entecavir therapy. The baseline IP-10 level was also positively associated with several clinical parameters, including baseline levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), hepatitis B virus (HBV) DNA, and hepatitis B surface antigen (HBsAg), and with the decrease in HBsAg levels after treatment. In addition, monocyte-derived IP-10 was expressed at higher levels in patients with CHB than in patients with liver cirrhosis (LC) and healthy controls (HC). According to the results of our in vitro experiments, IP-10 directly promoted hepatocyte apoptosis. Based on these findings, baseline serological and histological IP-10 levels might predict CHB severity and the decrease in HBsAg levels after entecavir therapy.
Keywords: chronic hepatitis B, entecavir, IP-10, prediction


Current Issue

30 June 2017 Volume 40,
Number 6, pp. 379~439

This Article


Cited By Articles
  • CrossRef (0)

Social Network Service
Services

Indexed in